SEC Form 4 · accession 0000914190-17-000395
NEPHROS INC · NEPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur H Amron
Director
Period of report
Dec 20, 2017
Accepted (ET)
Dec 22, 2017 · 11:37 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001196298
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 20, 2017 | A | 73,864 | $0.00 | A | 73,864 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $0.4999 | Dec 20, 2017 | A | 40,284 | A | — | Dec 27, 2027 | Common Stock | 40,284 | 40,284 | D |
Explanation of responses
- F1On December 20, 2017, the Company granted 73,864 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Amron in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). At the request of Mr. Amron, the Restricted Stock was granted to Wexford Capital LP. The Restricted Stock vests 6 months following the grant date.
- F2On December 20, 2017, the Company granted an option to purchase 40,284 shares of common stock of the Company (the "Option") in respect of the service by Mr. Amron as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. At the request of Mr. Amron, the Option was granted to Wexford Capital LP. The Option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19.